Hemispherx, another round.
Just received a new edition of a domestic exchange newsletter (which had otherwise a quite good standing).
A full page is dedicated to our old lady o roll, HEB, incredible:
As always, a disclaimer is missing.
Basic Points:
-30 year-old company, not just a startup, unique over the world (tsk)
-Market Cap of $140 Mio is treated "cheap" (!)
-Ampligen mentioned: only 30% failure in treatment.., it is "rumoured" that an application in Europe is to expected "in short time".
It should also be fast-acting against HIV.
-"Analysts" (unnamed) calculated that a 1% market share (of the 2.5 Mill CFS patients) would give the company earnings of $1.60
-rumoured a Nasdaq and German New Market listing, which should increase the focus, and "hence" achieve a "fair valuation".
-comparable companies valued 3x more expensive (but no other companies named, and no measurement criteria given)
The articles closes with a "speculative buy" rating, but buyers should use a S/L of $5.
...
Buyers, beware
IS.com |
